New 2026 Changing scenario in prevention and management of CMV infections in pediatric hematopoietic stem cell transplant patients Group Infectious Diseases Working Party (IDWP) 1st listed author Federica Galaverna Journal Bone Marrow Transplant.
New 2026 Defibrotide for prophylaxis of sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) in pediatric high-risk patients: consensus guidelines from the European Society for Blood and Marrow Transplantation (EBMT) Group Paediatric Diseases Working Party (PDWP) 1st listed author Selim Corbacioglu Journal Bone Marrow Transplant.
New 2026 Outcomes of patients with HTLV-1 adult T-cell leukemia/lymphoma (ATLL) after allogeneic SCT: results of the EBMT LWP Group Lymphoma Working Party (LWP) 1st listed author Patricia López-Pereira Journal Bone Marrow Transplant.
New 2025 Allogeneic haematopoietic cell transplant in cutaneous T-cell lymphomas: Recommendations from the EBMT PH&G Committee Group Lymphoma Working Party (LWP) Practice Harmonisation and Guidelines Committee 1st listed author Gandhi Damaj Journal J Eur Acad Dermatol Venereol.
New 2025 Allogeneic haematopoietic cell transplantation in peripheral T-cell lymphoma: recommendations from the EBMT Practice Harmonisation and Guidelines Committee Group Lymphoma Working Party (LWP) Practice Harmonisation and Guidelines Committee 1st listed author Gandhi Damaj Journal Lancet Haematol.
New 2025 Ask, do not tell: consulting a patient advisory board to understand unmet needs of patients with GVHD in Europe Group Patient Advocacy Committee Other society 1st listed author Hélène Schoemans Journal Lancet Haematol.
New 2025 Definition of relapse criteria in patients with rapidly progressive systemic sclerosis treated with autologous haemopoietic stem cell transplantation Group Autoimmune Diseases Working Party (ADWP) 1st listed author Nicoletta Del Papa Journal Bone Marrow Transplant.
New 2025 A European survey on allogeneic haematopoietic cell transplantation for myelofibrosis on behalf of the Chronic Malignancies Working Party of the EBMT: focus on 'real world' experience of JAK inhibitors, splenomegaly management and novel agents in the transplant algorithm Group Chronic Malignancies Working Party (CMWP) 1st listed author Alexandros Rampotas Journal Bone Marrow Transplant.
New 2025 Post-transplantation cyclophosphamide and antithymocyte globulin in 8/10 HLA-mismatched unrelated donor transplantation: the analysis on behalf of the transplant complications working party of the EBMT Group Transplant Complications Working Party (TCWP) 1st listed author Ivan Moiseev Journal Bone Marrow Transplant.
New 2025 Complications of Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-A Prospective Study on Behalf of the EBMT Transplant Complications Working Party Group Transplant Complications Working Party (TCWP) 1st listed author Agnieszka Tomaszewska Journal Cancers (Basel).
2025 Current capacity and gaps in viral vector manufacturing: a survey of centers associated with CTIWP of EBMT, NXTGEN-hightech, DARE-NL, T2EVOLVE, and GoCART coalition Group Cellular Therapy & Immunobiology Working Party (CTIWP) GoCART Coalition Other society 1st listed author Ganesh Ramesh Journal Bone Marrow Transplant.
2025 Posttransplant cyclophosphamide versus antithymocyte globulin in patients with cardiovascular comorbidity undergoing allogeneic hematopoietic cell transplantation for acute myeloid leukaemia in first complete remission from unrelated donors: a retrospective matched-pair analysis from the ALWP of the EBMT Group Acute Leukemia Working Party (ALWP) 1st listed author Jan Vydra Journal Bone Marrow Transplant.